Institute of Pathology, University of Bern, Murtenstrasse 31, 3008, Bern, Switzerland.
Pathology Unit, Department of Medicine (DIMED), University of Padua, Via Gabelli, 61 35121, Padova, Italy.
Virchows Arch. 2021 Dec;479(6):1085-1090. doi: 10.1007/s00428-021-03090-w. Epub 2021 Apr 12.
Tumor budding scoring guidelines from the International Tumor Budding Consensus Conference (ITBCC) for colorectal cancer propose three groups: BD1 (0-4 buds/0.785 mm), BD2 (5-9 buds/0.785 mm), and BD3 (10 or more buds/0.785 mm). Here, we investigate whether a fourth scoring category, namely zero buds, may have additional clinical relevance. The number of tumor buds/0.785 mm was scored in 959 cases. Those with zero tumor buds were considered BD0, while a new BD1 category of 1-4 buds was proposed. Associations of both scoring approaches with clinicopathological features were analyzed. Conventional ITBCC scoring showed expected associations with unfavorable histopathological prognostic factors. In total, 111/959 (11.6%) were BD0. A significant difference was found when BD0 was compared statistically to BD1 (1-4 buds) for pT, TNM, tumor grade, and lymphatic, venous, and perineural invasion (p < 0.01, all). Tumors with BD0 occur relatively frequently and contribute additional information on tumor behavior. BD0 should be considered for subsequent ITBCC guidelines.
国际肿瘤内突共识会议(ITBCC)提出的结直肠癌肿瘤内突评分指南建议分为三组:BD1(0-4 个芽/0.785mm)、BD2(5-9 个芽/0.785mm)和 BD3(10 个或更多芽/0.785mm)。在这里,我们研究第四个评分类别,即零芽,是否具有额外的临床相关性。在 959 例病例中对肿瘤芽/0.785mm 的数量进行了评分。将无肿瘤芽的病例视为 BD0,同时提出了一个新的 BD1 类别,即 1-4 个芽。分析了两种评分方法与临床病理特征的相关性。传统的 ITBCC 评分与不利的组织病理学预后因素有预期的相关性。总的来说,959 例中有 111 例(11.6%)为 BD0。BD0 在统计学上与 BD1(1-4 个芽)比较时,pT、TNM、肿瘤分级、淋巴血管和神经周围侵犯存在显著差异(p<0.01,均)。BD0 肿瘤相对常见,并提供了关于肿瘤行为的额外信息。BD0 应在随后的 ITBCC 指南中考虑。